Since cytokines are implicated in chronic fatigue syndrome would administration of this help? WHOM DO WE ASK THAT SIMPLE QUESTION?
Study sheds light on chronic fatigue syndrome August 2017
The latest here:
Cannabinoids, Blood–Brain Barrier, and Brain Disposition
by
Fabrizio Calapai 1, Luigi Cardia 2
, Emanuela Elisa Sorbara 1, Michele Navarra 3, Sebastiano Gangemi 4, Gioacchino Calapai 1,* and Carmen Mannucci 1
Fabrizio Calapai 1, Luigi Cardia 2, Emanuela Elisa Sorbara 1, Michele Navarra 3, Sebastiano Gangemi 4, Gioacchino Calapai 1,* and Carmen Mannucci 1
1
Department of Biomedical and Dental
Sciences and Morphological and Functional Imaging, University of
Messina, 98125 Messina, Italy
2
Anesthesia, Intensive Care and Pain Therapy, A.O.U.G. Martino Messina, University of Messina, 98125 Messina, Italy
3
Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98166 Messina, Italy
4
School and Division of Allergy and
Clinical Immunology, Department of Experimental Medicine, University of
Messina, 98125 Messina, Italy
*
Author to whom correspondence should be addressed.
Pharmaceutics 2020, 12(3), 265; https://doi.org/10.3390/pharmaceutics12030265
Received: 28 January 2020 / Revised: 21 February 2020 / Accepted: 12 March 2020 / Published: 15 March 2020
(This article belongs to the Special Issue Drug Delivery to the Brain)
Potential therapeutic actions of the cannabinoids
delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are based on
their activity as analgesics, anti-emetics, anti-inflammatory agents,
anti-seizure compounds. THC and CBD lipophilicity and their neurological
actions makes them candidates as new medicinal approaches to treat
central nervous system (CNS) diseases. However, they show differences
about penetrability and disposition in the brain. The present article is
an overview about THC and CBD crossing the blood–brain barrier (BBB)
and their brain disposition. Several findings indicate that CBD can
modify the deleterious effects on BBB caused by inflammatory cytokines
and may play a pivotal role in ameliorating BBB dysfunction consequent
to ischemia. Thus supporting the therapeutic potential of CBD for the
treatment of ischemic and inflammatory diseases of CNS. Cannabinoids
positive effects on cognitive function could be also considered through
the aspect of protection of BBB cerebrovascular structure and function,
indicating that they may purchase substantial benefits through the
protection of BBB integrity. Delivery of these cannabinoids in the brain
following different routes of administration (subcutaneous, oral, and
pulmonary) is illustrated and commented. Finally, the potential role of
cannabinoids in drug-resistance in the clinical management of
neurological or psychiatric diseases such as epilepsy and schizophrenia
is discussed on the light of their crossing the BBB.
View Full-Text
No comments:
Post a Comment